Progesterone Receptor (PR) Antibody (Immunohistochemistry)

Progesterone Receptor (PR) Antibody (Immunohistochemistry)

The Progesterone Receptor (PR) Antibody is a crucial immunohistochemical marker for the diagnosis and prognosis of hormone-dependent tumors, especially breast carcinoma.
PR, also known as NR3C3 (Nuclear Receptor Subfamily 3, Group C, Member 3), is an intracellular steroid receptor that mediates the effects of progesterone, a key female hormone involved in menstrual regulation, pregnancy, and mammary gland development.

The expression of PR in breast tumors is often associated with favorable prognosis and better response to endocrine therapies such as Tamoxifen and Fulvestrant.
In IHC staining, PR shows brown nuclear positivity in tumor cells, indicating the presence of progesterone receptors.

🔬 Features and Benefits

• Essential marker for breast and endometrial cancers

• Predictive of hormone therapy response

• Clear brown nuclear staining pattern

• Compatible with FFPE tissues and DAB detection systems

• Excellent stability: 18-month shelf life at 2–8 °C

💡 Diagnostic Applications

• Detection of PR-positive breast carcinoma

• Evaluation of endometrial and ovarian tumors

• Assessment of response to anti-hormonal therapy

• Research on progesterone signaling and hormonal regulation

🌐 Fardad Azma Rad Co.

Fardad Azma Rad Co., the exclusive representative of Talent Biomedical in Iran, supplies high-quality immunohistochemistry antibodies, including Progesterone Receptor (PR).
With a strong focus on scientific accuracy, diagnostic reliability, and international standards, Fardad Azma Rad supports pathology and molecular diagnostic laboratories across Iran.

“Download Brochure”